More articles about Drug Discovery & Development

The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The company has yet to release formal studies, but discussed two cases that illustrate the potential benefit of the methodology in improving patient treatment.

The companies will use their respective technologies to discover novel modulators of G-protein coupled receptors and ion channel targets.

Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.

Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.

Base Pair provides custom aptamer discovery and development services, as well as a line of catalog aptamers.

Regeneron Pharmaceuticals

Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.

The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

The consortium aims to identify tuberculosis protein targets and corresponding small molecule inhibitors that can be used to develop drugs to shorten therapy duration.

By analyzing EMRs and genomic data, Mendel Health believes its AI platform can identify patients for ongoing trials and help clinicians select treatments.

The partners will integrate genomic analyses and de-identified clinical data into Goldfinch's genomic registry of kidney disease patients.

Gyros Protein Technologies will distribute Euro Diagnostica's reporter gene cell lines in Europe and North America.

The company is developing a bioinformatics platform that searches billions of molecules to generate a library of compounds to manipulate cell biology.

Verge is working with four academic institutions to create a broad resource for the translation of preclinical models of amyotrophic lateral sclerosis research.

The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.

Thermo Fisher has acquired the contract development and manufacturing organization for $35 per share in cash.

Researchers from Hong Kong imputed transcriptomes from GWAS data and compared them to drug-induced gene expression profiles.

Pages

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.